AAPG Ascentage Pharma Group Internat - Fundamental Analysis

BEARISH

AAPG Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$24.93

Analyst Target

$45.71

+83.4% Upside

52W High

$48.45

52W Low

$17.55

Overview AI Snowflake Price Valuation Profitability Growth Health Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Feb 21, 2026

Market cap

$2.33B

P/E

N/A

ROE

-159.6%

Profit margin

-296.8%

Debt/Equity

2.54

Dividend yield

N/A

AI Analysis

Confidence Score

85%

Analysis Accuracy

AAPG's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range for biotech firms, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, including a -296.77% profit margin and negative ROE, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, this is overshadowed by massive losses and a debt/equity ratio of 2.54. The stock trades at a premium valuation (Price/Book: 88.88) with no earnings or cash flow support, and analysts' target price of $45.71 appears disconnected from current fundamentals.

Key Strengths

High gross margin of 90.87% suggests strong product-level pricing power or low production costs

Insider sentiment at 40/100 indicates some level of internal confidence despite overall caution

52-week high of $48.45 shows historical price resilience and potential for recovery

Peer benchmarking shows similar high growth expectations in sector (avg revenue growth 61.93%)

Positive 1-year return of +26.7% reflects recent market optimism despite fundamentals

Key Risks

Piotroski F-Score of 4/9 signals weak financial health and deteriorating operational efficiency

Negative profit margin (-296.77%) and ROE (-159.65%) indicate severe unprofitability

71.6% YoY revenue decline suggests core business contraction or failed product launches

Debt/Equity ratio of 2.54 is high for a biotech, increasing financial leverage risk

No available cash flow, earnings, or dividend data undermines sustainability and investor returns

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Weak

Key drivers: Low Piotroski F-Score (4/9), Negative profitability and revenue contraction, High valuation without earnings support, No Altman Z-Score available (risk of distress)

Confidence

88%

Value

25/100

Ref P/E, PEG, Graham Number

Positives

High gross margin may support future profitability if scaled
Price/Sales of 5.97 is below some peers (e.g., ADPT at 6.5+), suggesting relative valuation appeal

Watchpoints

Price/Book of 88.88 is extremely high for a loss-making firm
No Graham Number or intrinsic value available due to negative earnings
Forward P/E of -51.86 indicates deep unprofitability

Future

30/100

Ref Growth rates

Positives

Analyst target price of $45.71 implies strong growth expectations
Sector average revenue growth is 61.93%, suggesting high-growth potential in biotech

Watchpoints

71.6% YoY revenue decline contradicts growth narrative
No forward earnings or cash flow data to validate growth assumptions
Negative ROIC and lack of operating cash flow hinder reinvestment capacity

Past

35/100

Ref Historical trends

Positives

5-year return of +43.4% shows strong historical performance
1-year return of +26.7% indicates recent market momentum

Watchpoints

Two quarters with no earnings estimates or actuals, indicating poor transparency
6-month return of -48.0% reflects sharp recent pullback
No consistent earnings history to assess trend reliability

Health

20/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Current ratio of 1.54 and quick ratio of 1.40 suggest short-term liquidity adequacy
No Altman Z-Score available, but Piotroski F-Score of 4/9 is below threshold for stability

Watchpoints

Piotroski F-Score of 4/9 is in the 'Weak' range, indicating deteriorating financial health
Debt/Equity of 2.54 is high for a biotech, increasing financial risk
Negative ROA (-22.77%) and ROE (-159.65%) signal poor capital efficiency

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

Dividend yield and payout ratio are both 0.00%
No history of dividend payments or intent

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$24.93

Analyst Target

$45.71

Upside/Downside

+83.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for AAPG and closest competitors.

Updated 2026-02-20

Company	5Y	3Y	1Y	6M	1M	1W
AAPG Ascentage Pharma Group Internat Primary	+43.4%	+43.4%	+26.7%	-48.0%	-5.5%	+4.7%
ADPT Adaptive Biotechnologies Corporation Peer	-73.2%	+72.7%	+82.5%	+16.9%	-13.5%	-5.2%
ATEC Alphatec Holdings, Inc. Peer	+4.7%	+20.4%	+33.9%	+44.4%	-24.8%	-11.9%
BHC Bausch Health Companies Inc. Peer	-78.1%	-29.4%	-24.3%	-12.7%	-17.7%	-15.3%
ADUS Addus HomeCare Corporation Peer	-0.0%	+9.6%	+3.0%	-2.5%	+5.2%	+1.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-51.86

N/A

88.88

5.97

21.07

-7.88

$2.33B

Profitability

Profit margins and return metrics

Profit Margin -296.77%

Operating Margin -237.05%

Gross Margin 90.87%

ROE -159.65%

ROA -22.77%

Growth

Revenue and earnings growth rates

Revenue Growth -71.6%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

2.54

High debt

Current Ratio

1.54

Good

Quick Ratio

1.4

Good

Cash/Share

$4.83

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-26

$N/A

2025-08-07

$N/A

Healthcare Sector Comparison

Comparing AAPG against 146 companies in the Healthcare sector (11 bullish, 60 neutral, 75 bearish)

Return on Equity (ROE)

-159.65%

This Stock

-56.86%

Sector Avg

+180.8% (Excellent)

Profit Margin

-296.77%

This Stock

-20.8%

Sector Avg

+1327.0% (Superior)

Debt to Equity

2.54

This Stock

2.68

Sector Avg

-5.3% (Lower)

Revenue Growth

-71.6%

This Stock

62.23%

Sector Avg

-215.1% (Slower)

Current Ratio

1.54

This Stock

3.45

Sector Avg

-55.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
AAPG Ascentage Pharma Group Internat	BEARISH	$2.33B	-	-159.6%	-296.8%	$24.93
ADPT Adaptive Biotechnologies...	BEARISH	$2.34B	-	-27.8%	-21.5%	$15.2
ATEC Alphatec Holdings, Inc.	BEARISH	$2.32B	-	-540.4%	-21.3%	$15.62
BHC Bausch Health Companies Inc.	BEARISH	$2.19B	6.79	563.2%	3.6%	$5.91
ADUS Addus HomeCare Corporation	BULLISH	$2.13B	24.83	8.6%	6.4%	$115.48

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

7 analysts

Oppenheimer

2025-12-04

init

Outperform

Truist Securities

2025-11-24

init

Buy

BTIG

2025-11-10

init

Buy

Piper Sandler

2025-11-05

init

Overweight

Past News Coverage

Recent headlines mentioning AAPG from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends